Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84678 | 0.97 | — | — | |
| Iodide SCHEMBL29051968 | 0.95 | — | — | |
| Bromide SCHEMBL29051995 | 0.95 | — | — | |
| SCHEMBL22626273 | 0.77 | — | — | |
| SCHEMBL3185782 | 0.75 | CYP2A6 (0.36) | — | |
| Isophthalic Acid SCHEMBL28071489 | 0.74 | LCK (0.47) | — | |
| Hydrochloric Acid SCHEMBL16333503 | 0.74 | — | — | |
| SCHEMBL14869616 | 0.72 | LMNA (0.47) | — | |
| SCHEMBL16375393 | 0.72 | CYP2A6 (0.52) | — | |
| SCHEMBL10459073 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152014-B2 | Therapeutic compounds and compositions | eXlthera Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2024-02-22 | — | — | US | disclosed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-116390609-A | Perovskite thin film, preparation method thereof and perovskite solar cell | 中国长江三峡集团有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| CN-1533374-B | Substitutled cyclohexane-1,4-diamine derivatives | GRUENETHAL GMBH | 2013-08-21 | — | — | CN | disclosed |
| CN-1972916-B | Cinnamide compounds | EISAI R&D MAN CO LTD | 2013-03-27 | — | — | CN | disclosed |
| CN-101723900-B | Cinnamide compounds | EISAI R&D MAN CO LTD | 2012-08-22 | — | — | CN | disclosed |
| CN-101723900-A | Cinnamide compounds | EISAI R&D MAN CO LTD | 2010-06-09 | — | — | CN | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| CN-1972916-A | Cinnamide compounds | EISAI R&D MAN CO LTD (JP) | 2007-05-30 | — | — | CN | disclosed |
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTIALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| CN-1533374-A | Substitutled cyclohexane-1,4-diamine derivatives | — | 2004-09-29 | — | — | CN | disclosed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1216244-A1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | Aventis Pharmaceuticals Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019821-A1 | BENZISOXAZOLYL-, PYRIDOISOXAZOLYL- AND BENZTHIENYL-PHENOXY DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| US-5939398-A | ANTIATHEROSCLEROSIS AGENTS | PFIZER INC. (US) | 1999-08-17 | — | — | US | disclosed |